Noubar Afeyan discusses the potential of a coronavirus booster shot on ‘The Claman Countdown’
Moderna, one of the leading COVID-19 vaccine providers, is set to join the S&P 500, the broadest measure of the U.S. stock market.
Shares jumped in morning trading adding to its annual gain of over 148%.
The inclusion may require mutual fund investors that mirror the benchmark to buy the stock which can often drive further gains.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| MRNA | MODERNA, INC. | 259.68 | +13.02 | +5.28% |
The biotech company, which has already delivered over 100 million COVID-19 vaccines, will replace Alexion Pharmaceuticals Inc., which is being acquired by AstraZeneca on July 21 according to S&P Dow Jones Indices.
| Ticker | Security | Last | Change | Change % |
|---|---|---|---|---|
| ALXN | ALEXION PHARMACEUTICALS, INC. | 180.51 | -6.10 | -3.27% |
| AZN | ASTRAZENECA PLC | 56.96 | -2.84 | -4.75% |
Moderna is on track to deliver 1 billion COVID-19 vaccine doses this year and is aiming to increase that number by 2022 to up to 3 billion doses.
